Daisuke Kotani, GI Medical oncologist, Chief physician at Department of Gastrointestinal Oncology at National Cancer Center Hospital East, Japan, shared a post on X about a recent article by L. Boscolo Bielo et al., published in ESMO OPEN:
“High-TMB after anti-EGFR therapy in MSS CRC
- TMB ≥10 (after vs before anti-EGFR): 33.8% vs 9.7%
- Higher alterations of MAPK signaling
Could high-TMB accompanied by ‘subclonal’ alterations after anti-EGFR therapy be a target for immunotherapy?”
Title: Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy
Authors: L. Boscolo Bielo, S. Napolitano, A. Avallone, F. Pietrantonio, R. Bordonaro, E. Maiello, S. Pisconti, E. Tamburini, C. Lotesoriere, G. Tortora, A. Zaniboni, L. Blasi, L. Antonuzzo, R. Berardi, P. Tagliaferri, C. Cremolini, S. Lonardi, C. Garufi, C. Pinto, E. Ongaro, G. Santabarbara, M. Scartozzi, V. De Falco, A. De Stefano, C. Cardone, A. Iacovucci, M.F. Bosco, A.E. Russo, T.P. Latiano, C. Nisi, M. Messina, N. Salmistraro, A. Sartore-Bianchi, S. Siena, M.G. Zampino, N. Fazio, N. Normanno, A. Febbraro, L.P. Guerrera, P. Parente, F. De Vita, E. Martinelli, T. Troiani, G. Curigliano, F. Ciardiello, G. Martini, D. Ciardiello
Read the Full Article on ESMO OPEN
More posts featuring Daisuke Kotani.